Table 2.

Unadjusted and adjusted incidence rate ratios during the study period

	Unadjusted				Adjusteda
	Inflammatory bowel disease	Non-immune-mediated	Rate ratio of IBD vs. non-immune-mediated (95% CI)b	p value	Rate ratio of IBD vs. non-immune-mediated (95% CI)b	p value
	(n = 34,687)	(n = 34,687)
Total person-years	47,233	44,315
Total number of TEs	9087	4186
Event rate per year	0.192	0.094	2.04 (1.78, 2.34)	< 0.01	1.49 (1.30, 1.71)	< 0.01
Total number of DVT events	4188	1049
Event rate per year	0.089	0.024	3.75 (3.02, 4.64)	< 0.01	2.44 (2.00, 2.99)	< 0.01
Total number of PE events	2273	677
Event rate per year	0.048	0.015	3.15 (2.34, 4.24)	< 0.01	1.90 (1.42, 2.54)	< 0.01
Total number of IS events	2163	1535
Event rate per year	0.046	0.035	1.32 (1.03, 1.69)	0.026	1.15 (0.89, 1.50)	0.278
Total number of MI events	901	1046
Event rate per year	0.019	0.024	0.81 (0.59, 1.11)	0.187	0.62 (0.44, 0.88)	0.008

CI confidence interval, DVT deep vein thromboembolism, IBD inflammatory bowel disease, IS ischemic stroke, MI myocardial infarction, PE pulmonary embolism, TE thromboembolic event. The study period was defined as the time from the index date until the earliest of patient death, end of continuous eligibility or end of data availability

^aThe adjusted incidence rate ratios controlled for the following: cohort assignment, age at index date, sex (female), baseline comorbidities, baseline non-immune-mediating drugs and baseline TE of interest (yes/no)

^bIncidence rate ratios, 95% confidence intervals and p-values were estimated using generalized linear models with a Poisson distribution and a sandwich (robust) variance estimator. An offset was used to account for varying lengths of follow-up time